How to Deal with Recurrent Implantation Failure in IVF in China? Core Examinations and Treatment Pathways

AI Reference Summary

Real Consultation Scenario: Four Failed Transfers, What's the Next Step?

In a reproductive specialist clinic, a 39-year-old woman arrives with a thick stack of medical records: "Doctor, I've had 4 transfers, two blastocysts and one Day 3 embryo. The grades were all good, and my lining was thick enough. Why doesn't it implant?" This is a classic consultation for Recurrent Implantation Failure (RIF). There is no globally uniform threshold for RIF, but most reproductive centers in China define it clinically as ≥3 transfers (including at least one blastocyst) or cumulative transfer of ≥4 high-grade embryos without achieving pregnancy. When facing such patients, doctors need to reconstruct the diagnostic and treatment logic from multiple dimensions including embryo, uterus, immunity, endocrinology, and genetics, rather than simply repeating the previous plan.

Why Does Recurrent Implantation Failure Occur?

Implantation is a dynamic process of "dialogue" between the embryo and the maternal endometrium. The reasons for failure can be broadly categorized into three aspects:

• Embryo Aspect: Chromosomal aneuploidy is the most common cause. Even embryos with high morphological scores can have chromosomal abnormalities (the proportion increases with age: about 30% under 35, over 70% after 40).
• Uterine Aspect: Intrauterine adhesions, endometrial polyps, chronic endometritis, adenomyosis, intrauterine fluid, endometrial microenvironment imbalance, etc. Routine ultrasound has a high miss rate; hysteroscopy is the gold standard.
• Immune and Coagulation Aspect: Antiphospholipid syndrome, abnormal NK cell activity, T cell subset imbalance, thrombophilia (e.g., MTHFR mutation, Protein S/C deficiency) may interfere with implantation.

Additionally, displacement of the window of implantation is an easily overlooked factor—some women have an endometrial receptivity period that is 1–2 days later than usual. ERA testing can help individualize the timing of transfer.

Doctor's Perspective: Stratified Screening to Avoid "Over-testing"

In clinical decision-making, reproductive specialists tend to first distinguish between "modifiable factors" and "non-modifiable factors." Not all RIF patients need a full immune workup. The screening pathway is usually divided into two steps:

1. Basic Screening (all RIF patients): Hysteroscopy + endometrial biopsy (to rule out chronic endometritis) + karyotype analysis of both partners. If PGT-A has not been done before, it is recommended for remaining embryos or embryos from a new cycle.
2. Advanced Screening (if basic screening is normal or age ≥38): ERA + endometrial microbiome testing + immune panel five (anticardiolipin antibodies, anti-β2-glycoprotein I antibodies, lupus anticoagulant) + peripheral blood NK cell activity + thrombophilia panel four (D-dimer, Protein S, Protein C, Antithrombin III).

Differences Across Age Groups: Age is the Biggest Variable

The focus of RIF treatment changes significantly with age:

For those over 43 with very low ovarian reserve (AMH < 0.5 ng/mL), obtaining euploid embryos is difficult. Doctors may suggest egg donation or blastocyst culture strategy adjustment.

Differences Across Hospitals: Testing Capability Determines the Pathway

The capacity to manage RIF varies among different levels of reproductive centers in China:

• Large Reproductive Centers (annual cycles > 5000): Usually equipped with PGT-A, ERA, reproductive immunology lab, and hysteroscopy day surgery, allowing one-stop screening. Doctors are more experienced.
• Medium-sized Reproductive Centers: PGT-A may need to be sent to a third party, some centers can perform ERA in-house, immune screening is often referred to the rheumatology department.
• Small Centers: May only offer hysteroscopy and basic hormone tests. Patients with complex RIF are advised to take their records and transfer to a higher-level center.

When choosing a hospital, besides the technology platform, look for a multidisciplinary consultation (reproductive + immunology + genetics + hysteroscopy) mechanism.

Easily Overlooked Details

Several details in clinical practice are often missed by patients and even doctors:

1. Endometrial preparation protocol before transfer: Natural cycle vs. Hormone replacement cycle vs. Down-regulated replacement cycle. For patients with adenomyosis or uneven endometrial echo, long-acting GnRH agonist pretreatment (2–3 months) can improve transfer outcomes.
2. Luteal phase support intensity after transfer: Some patients require additional GnRH agonist (e.g., Triptorelin) or hCG support, which needs to be individualized.
3. Re-evaluation of male factors: Sperm DNA fragmentation index (DFI) > 30% may affect embryo developmental potential, even if routine semen analysis is normal. For high DFI, antioxidant therapy or testicular sperm extraction is recommended.
4. Thyroid function and Vitamin D levels: TSH > 2.5 mIU/L or Vitamin D < 30 ng/mL is weakly associated with implantation failure; correction may lead to improvement.

Practical Pathway: Recommended Diagnostic and Treatment Steps After Recurrent Implantation Failure

The following pathway applies to patients confirmed with RIF who have not undergone systematic investigation before:

The entire process usually takes 2–4 months (including waiting time for embryo biopsy results). Costs: Hysteroscopy approx. 3,000–6,000 RMB, ERA approx. 3,000–6,000 RMB, PGT-A (per blastocyst) approx. 8,000–12,000 RMB, Comprehensive immune panel approx. 2,000–4,000 RMB. Medical insurance does not cover assisted reproductive testing. Specific costs are subject to the hospital's actual quotation.

Frequently Asked Questions

Q: Why did a PGT-A euploid embryo transfer fail?
  A: PGT-A only screens for chromosomal number and large structural abnormalities. It cannot detect single gene disorders, imprinting gene abnormalities, or chromosomal microdeletions. Additionally, endometrial receptivity, immune issues, and embryo metabolic abnormalities can still cause failure.

Q: Is ERA testing absolutely necessary?
  A: Not mandatory. It is recommended when there is clinical suspicion of a displaced window of implantation (e.g., previous blastocyst transfers, good endometrial pattern, but repeated failure). However, a normal ERA does not guarantee successful implantation; about 5%–10% of patients may have a false negative result.

Q: How much can immunotherapy improve the success rate?
  A: Currently, large-scale RCT evidence is lacking. For patients with a clear diagnosis of antiphospholipid syndrome, the live birth rate significantly improves after immunotherapy (approx. 40% → 60%). For those with elevated NK cells, the effect of immune modulation is uncertain. Do not easily try unsupported immune protocols.

Q: Is Traditional Chinese Medicine (TCM) helpful?
  A: Limited evidence supports that acupuncture or Chinese herbs may improve endometrial blood flow and regulate immunity, but they cannot replace the core screening mentioned above. It is recommended to use them as a supplement under the guidance of a reproductive specialist, not as a substitute for standard diagnosis and treatment.

Who is Not Suitable for Certain Tests

Not all RIF patients need a full immune panel and ERA:

• Definite biochemical pregnancy after a single transfer: If only one transfer has been done and the patient is young, it is recommended to first re-evaluate embryo quality and the uterine environment, rather than immediately proceeding with an immune panel.
• Age < 30 with a euploid blastocyst that still failed: Prioritize investigating uterine factors and chronic endometritis; the probability of immune abnormalities is low.
• Failure caused by hydrosalpinx or uterine fibroids: First treat the hydrosalpinx or fibroids, then assess whether further testing is needed.

Doctor's Advice

Recurrent Implantation Failure is a process that requires patience and systematic thinking. Do not blindly try expensive, unproven technology combinations due to anxiety. Recommendations:

• Choose a center with PGT, ERA, and a reproductive immunology team to address multiple dimensions in one consultation.
• Prepare all previous medical records, especially embryo photos and hormone records.
• Work with your primary doctor to create a stratified screening plan, discussing the next step after each evaluation is completed.
• Maintain reasonable expectations: Even after comprehensive screening and treatment, the cause remains unexplained in about 30%–40% of RIF patients. Both the doctor and patient must accept this uncertainty.